Examples of using Nuedexta in English and their translations into German
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
How is Nuedexta used?
Other information about Nuedexta.
Why has Nuedexta been approved?
What is the risk associated with Nuedexta?
Nuedexta must not be used in patients.
For the full list of all side effects reported with Nuedexta, see the package leaflet.
Nuedexta was compared with placebo(a dummy treatment) for 12 weeks.
A review of the patient's current medicines is anessential part of the evaluation of patients for whom treatment with NUEDEXTA is proposed.
Nuedexta is a medicine that contains two active substances, dextromethorphan and quinidine.
Take care if you consume alcohol while you are taking NUEDEXTA as might increase the risk of side effects such as dizziness and sleepiness.
Nuedexta is suitable only for the treatment of PBA, not for other causes of emotional lability.
Given the pharmacodynamic and pharmacokinetic interactions, concomitant use of NUEDEXTA and TCAs is not recommended due to the elevated risk of serotonin syndrome see section 4.5.
Nuedexta has been studied in one main study involving 326 patients with PBA due to multiple sclerosis or amyotrophic lateral sclerosis.
Depending on your response to the treatment, your doctor may either decide: to continue the treatment with NUEDEXTA 15 mg/9 mg capsules, or to give you a higher dose and to prescribe NUEDEXTA 23 mg/9 mg capsules to you.
When NUEDEXTA is used with other serotoninergic medicines, the risk of“serotonin syndrome” may be increased due to pharmacodynamic interaction.
In this placebo-controlled 12-week study, 326 PBA subjects with underlying ALS or MS were randomized to receive NUEDEXTA 15 mg/ 9 mg,(n=107), NUEDEXTA 23 mg/ 9 mg(n=110), or placebo(n=109) for 12 weeks.
If the clinical response with NUEDEXTA 15 mg/9 mg is adequate, the dose taken in weeks 2-4 should be continued.
Because of this effect on CYP2D6, accumulation of parent drug substances and/or failure of active metabolite formation may affect the safety and/or theefficacy of medicinal products used concomitantly with NUEDEXTA that are metabolised by CYP2D6 see section 4.5.
After 12 weeks of treatment with Nuedexta, the CNS-LS score decreased by 8.2 points, compared with a decrease of 5.7 points for placebo.
While therapeutic doses of quinidine for treatment of cardiac arrhythmia or malaria are generally≥10- fold higher than the dose of quinidine in this medicinal product, potentially fatal cardiac arrhythmia, including torsades de pointes,can occur at quinidine exposures that are possible from NUEDEXTA overdose.
Regardless of which strength of NUEDEXTA has been prescribed to you: continue the treatment with: two capsules per day one capsule every 12 hours.
As NUEDEXTA may cause harm to your unborn baby, its use is not recommended when you are pregnant or if you are a women of childbearing potential not using contraception.
The card should contain details to alert any HCP treating the patient that they are being treated with Nuedexta and of the potential for interaction once a patient is on treatment with Nuedexta and another treatment is added.
The CHMP concluded that Nuedexta is effective in treating the symptoms of PBA based on the studies in patients with PBA caused by multiple sclerosis and amyotrophic lateral sclerosis.
The MAH shall ensure that, following discussion and agreement with the National Competent Authorities in each Member State where Nuedexta is marketed, at launch and after launch, all healthcare professionals who are expected to prescribe Nuedexta are provided with the following items.
Do not take NUEDEXTA if you have taken these antidepressants during the last two weeks and allow at least 14 days after stopping NUEDEXTA before starting an MAOI.
The company will also carry out a study on the use of Nuedexta and a study to monitor Nuedexta's safety including its effects on the heart and potential for interactions with other medicines.
If the clinical response with NUEDEXTA 15 mg/9 mg is inadequate, NUEDEXTA 23 mg/9 mg should be prescribed, taken two times per day, one in the morning and one in the evening, 12 hours apart.
The adverse reactions consideredat least possibly related to treatment with NUEDEXTA in the placebo-controlled and the open-label extension phase of the above mentioned clinical study are listed below by body system organ class and frequency. very common≥1/10.
In addition, the maintenance of the clinical effect of NUEDEXTA in the patient should be regularly monitored in the long-term against its tolerability, in order to ascertain the continued benefit of the product.